Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pimecrolimus: a review.

A K Gupta1, M Chow

  • 1Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Science Center (Sunnybrook site) and the University of Toronto, Toronto, Canada. agupta@execulink.com

Journal of the European Academy of Dermatology and Venereology : JEADV
|August 28, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peripheral edema due to nifedipine-itraconazole interaction: a case report.

Archives of dermatology·1996
Same author

High frequency 40-MHz ultrasound. A possible noninvasive method for the assessment of the boundary of basal cell carcinomas.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·1996
Same author

Effect of ionizing radiation on AP-1 binding activity and basic fibroblast growth factor gene expression in drug-sensitive human breast carcinoma MCF-7 and multidrug-resistant MCF-7/ADR cells.

The Journal of biological chemistry·1995
Same author

Role of cellular casein kinase II in the function of the phosphoprotein (P) subunit of RNA polymerase of vesicular stomatitis virus.

The Journal of biological chemistry·1995
Same author

Fundus imaging in patients with cataract: role for a variable wavelength scanning laser ophthalmoscope.

The British journal of ophthalmology·1995
Same author

Age and gender differences in the impact of psoriasis on quality of life.

International journal of dermatology·1995
Same journal

Environmental criteria in dermatology research grants.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same journal

Microneedling with adipose MSC exosomes versus monotherapy for androgenetic alopecia.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same journal

Diabetes and melanoma: Impact on prognosis and healthcare costs.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same journal

Differential survival with adjuvant immunotherapy in stage III acral versus non-acral melanoma.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same journal

Estimating the global burden of mental health disorders associated with atopic dermatitis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same journal

Proteomic analysis in hidradenitis suppurativa reveals systemic inflammation in all disease stages.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
See all related articles

Pimecrolimus, an immunomodulating macrolactam, effectively treats inflammatory skin diseases by blocking T cell activation and cytokine synthesis. It offers a safe alternative to topical steroids, with minimal systemic effects and good tolerability in children and adults.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Pimecrolimus is a novel immunomodulating macrolactam developed for inflammatory skin conditions.
  • It possesses significant anti-inflammatory and immunomodulatory properties with low systemic immunosuppression.
  • Its mechanism involves blocking T cell activation and cytokine synthesis.

Purpose of the Study:

  • To evaluate the efficacy and safety of pimecrolimus in treating inflammatory skin diseases.
  • To compare pimecrolimus with existing treatments like topical steroids.
  • To assess its pharmacokinetic profile and adverse effects.

Main Methods:

  • Clinical studies in animal models and human subjects with allergic contact dermatitis and atopic dermatitis.
  • Comparative efficacy studies against control treatments and topical steroids.

Related Experiment Videos

  • Pharmacokinetic assessments of topical pimecrolimus application.

    • Main Results:

    • Pimecrolimus demonstrated significant efficacy in allergic contact dermatitis and atopic dermatitis in both animal models and human studies.
    • Topical pimecrolimus showed comparable efficacy to betamethasone-17-valerate without steroid-associated side effects like skin atrophy.
    • Studies in adults and children (3 months+) showed rapid improvement in atopic dermatitis, with minimal systemic absorption and transient local irritation.
    • Psoriasis treatment showed a dose-dependent effect under semi-occlusive conditions.

    Conclusions:

    • Pimecrolimus is an effective and safe treatment for inflammatory skin diseases, including atopic dermatitis and allergic contact dermatitis.
    • It offers a favorable adverse-effects profile with minimal impact on the systemic immune response.
    • Pimecrolimus represents a promising therapeutic option for various inflammatory skin conditions.